SAGE Therapeutics (SAGE) Price Target Raised to $261.00

SAGE Therapeutics (NASDAQ:SAGE) had its price objective raised by investment analysts at Royal Bank of Canada from $259.00 to $261.00 in a report released on Monday. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target points to a potential upside of 103.49% from the stock’s current price.

Other analysts have also issued research reports about the company. LADENBURG THALM/SH SH set a $235.00 target price on SAGE Therapeutics and gave the company a “buy” rating in a report on Wednesday, October 31st. Oppenheimer set a $170.00 target price on SAGE Therapeutics and gave the company a “buy” rating in a report on Monday, October 29th. Canaccord Genuity set a $220.00 target price on SAGE Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 8th. Stifel Nicolaus upped their target price on SAGE Therapeutics from $198.00 to $239.00 and gave the company a “buy” rating in a report on Tuesday, August 7th. Finally, Cowen reissued a “buy” rating and issued a $207.00 target price on shares of SAGE Therapeutics in a report on Thursday, November 1st. One analyst has rated the stock with a sell rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $203.63.

SAGE Therapeutics stock opened at $128.26 on Monday. The firm has a market capitalization of $6.42 billion, a price-to-earnings ratio of -18.09 and a beta of 2.76. SAGE Therapeutics has a fifty-two week low of $61.67 and a fifty-two week high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.41) by ($0.22). During the same quarter in the prior year, the business earned ($1.97) earnings per share. Equities research analysts forecast that SAGE Therapeutics will post -7.32 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SAGE. Dimensional Fund Advisors LP lifted its position in SAGE Therapeutics by 58.1% during the first quarter. Dimensional Fund Advisors LP now owns 46,362 shares of the biopharmaceutical company’s stock worth $7,468,000 after buying an additional 17,044 shares during the period. Principal Financial Group Inc. lifted its position in SAGE Therapeutics by 3.2% during the first quarter. Principal Financial Group Inc. now owns 12,406 shares of the biopharmaceutical company’s stock worth $1,998,000 after buying an additional 382 shares during the period. UBS Group AG lifted its position in SAGE Therapeutics by 242.6% during the first quarter. UBS Group AG now owns 23,493 shares of the biopharmaceutical company’s stock worth $3,785,000 after buying an additional 16,636 shares during the period. Millennium Management LLC lifted its position in SAGE Therapeutics by 103.5% during the first quarter. Millennium Management LLC now owns 52,592 shares of the biopharmaceutical company’s stock worth $8,471,000 after buying an additional 26,747 shares during the period. Finally, Legal & General Group Plc raised its holdings in shares of SAGE Therapeutics by 3.7% in the 1st quarter. Legal & General Group Plc now owns 17,581 shares of the biopharmaceutical company’s stock worth $2,831,000 after purchasing an additional 629 shares during the period.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Featured Article: Why is the conference call important?

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply